IMRX Projected Dividend Yield

Cl A/Immuneering Corp ( NASDAQ : IMRX )

Immuneering Corporation is a clinical-stage oncology company. Co. is engaged in the development of medicines for cancer patients with universal-RAS therapy. Co.'s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. Co.'s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway.

21 YEAR PERFORMANCE RESULTS